,Name,Term,ES,NES,NOM p-val,FDR q-val,FWER p-val,Tag %,Gene %,Lead_genes
0,prerank,KEGG_2021_Human__cGMP-PKG signaling pathway,-0.7064146118243904,-2.0320488416494182,0.0,0.0,0.0,14/41,7.39%,PPP3CA;ROCK1;ATP2B1;PPP1R12A;CREB5;GNAQ;AKT1;GNAI3;MEF2C;MEF2A;GNAI2;CALM1;PPP1CB;PLCB2
1,prerank,"KEGG_2021_Human__Parathyroid hormone synthesis, secretion and action",-0.7235075025008364,-2.0289727414436958,0.0,0.0,0.0,11/35,7.39%,FOS;CREB5;GNAQ;NR4A2;JUND;PRKCB;GNAI3;MEF2C;MEF2A;GNAI2;PLCB2
2,prerank,KEGG_2021_Human__Oxytocin signaling pathway,-0.6770432444564098,-2.0057746626793587,0.0,0.0011071293301867554,0.001,15/45,7.39%,PPP3CA;ROCK1;FOS;PTGS2;PPP1R12A;GNAQ;JUN;PRKCB;GNAI3;MEF2C;GNAI2;KRAS;CALM1;PPP1CB;PLCB2
3,prerank,KEGG_2021_Human__cAMP signaling pathway,-0.6246585161701508,-1.9797118677150807,0.0,0.0024910409929201995,0.003,17/53,9.96%,ROCK1;ATP2B1;FOS;PPP1R12A;CREB5;AKT1;JUN;VAV3;NFKBIA;GNAI3;ORAI1;GNAI2;CALM1;PPP1CB;PIK3CB;ACOX1;PIK3CD
4,prerank,KEGG_2021_Human__Focal adhesion,-0.6296632453483244,-1.9741607750568517,0.0,0.0019928327943361597,0.003,21/65,11.55%,TLN1;ROCK1;PAK2;PTEN;PPP1R12A;SOS2;VEGFA;AKT1;JUN;ACTN1;VAV3;ITGA4;PRKCB;GSK3B;PPP1CB;FLNA;PIK3CB;PIK3CD;PIP5K1B;SPP1;MAPK1
5,prerank,KEGG_2021_Human__Amphetamine addiction,-0.7931618708827655,-1.9385283712246864,0.0,0.002214258660373511,0.004,9/19,10.19%,PPP3CA;FOS;CREB5;JUN;PRKCB;SIRT1;CALM1;PPP1CB;FOSB
6,prerank,KEGG_2021_Human__Estrogen signaling pathway,-0.6587044908095513,-1.928996628961604,0.0,0.0028469039919087995,0.006,16/43,12.25%,FOS;CREB5;SOS2;GNAQ;AKT1;JUN;GNAI3;GNAI2;KRAS;CALM1;PLCB2;PIK3CB;HSP90AB1;PIK3CD;MAPK1;RARA
7,prerank,KEGG_2021_Human__Dopaminergic synapse,-0.6692672538818093,-1.9208366704496247,0.007518796992481203,0.003321387990560266,0.008,15/42,11.12%,PPP3CA;FOS;CREB5;GNAQ;AKT1;PRKCB;GNAI3;GSK3B;GNAI2;CALM1;PPP1CB;PLCB2;MAPK14;GNB1;GNG11
8,prerank,KEGG_2021_Human__Cholinergic synapse,-0.719680935441571,-1.9137512870762574,0.004830917874396135,0.0033213879905602656,0.009,15/29,11.55%,FOS;CREB5;GNAQ;AKT1;PRKCB;JAK2;GNAI3;GNAI2;KRAS;PLCB2;PIK3CB;GNB1;PIK3CD;GNG11;MAPK1
9,prerank,KEGG_2021_Human__Aldosterone synthesis and secretion,-0.7798401826145331,-1.90200931891721,0.003472222222222222,0.004317804387728346,0.013,9/18,7.39%,ATP2B1;NR4A1;CREB5;GNAQ;NR4A2;PRKCB;ORAI1;CALM1;PLCB2
10,prerank,KEGG_2021_Human__Renin secretion,-0.8083442692136972,-1.8978158372403213,0.0,0.003925276716116678,0.013,7/16,7.39%,PPP3CA;GNAQ;GNAI3;ORAI1;GNAI2;CALM1;PLCB2
11,prerank,MSigDB_Hallmark_2020__Hypoxia,-0.5779343694041206,-1.881372822897682,0.0,0.004982081985840399,0.017,24/68,13.66%,KLF6;HSPA5;FOS;ZFP36;VEGFA;PNRC1;MXI1;CITED2;NR3C1;PPP1R15A;JUN;UGP2;CCNG2;DDIT3;CDKN1B;ZNF292;PGK1;KLF7;MYH9;KLHL24;IER3;ERRFI1;DDIT4;BTG1
12,prerank,KEGG_2021_Human__Cellular senescence,-0.6081227127957115,-1.8622058519047267,0.0,0.007664741516677537,0.028,21/56,18.05%,PPP3CA;E2F2;PTEN;ZFP36L2;HIPK1;AKT1;SIRT1;KRAS;CALM1;PPP1CB;PIK3CB;MAPKAPK2;MAPK14;PIK3CD;MAPK1;MAP2K3;VDAC2;PPP3R1;MDM2;GADD45B;ZFP36L1
13,prerank,KEGG_2021_Human__Glutamatergic synapse,-0.7569418783985038,-1.8561522003181485,0.007874015748031496,0.008066227977074932,0.03,11/18,11.55%,PPP3CA;GNAQ;PRKCB;GNAI3;GNAI2;PLCB2;SLC38A2;GLUL;GNB1;GNG11;MAPK1
14,prerank,KEGG_2021_Human__Prostate cancer,-0.6472249521800958,-1.8557686506672688,0.0,0.007528479445269936,0.03,23/37,24.54%,E2F2;PTEN;CREB5;SOS2;AKT1;NFKBIA;GSK3B;KRAS;CDKN1B;PIK3CB;HSP90AB1;PIK3CD;MAPK1;BRAF;MDM2;MMP9;CTNNB1;EP300;MAP2K2;PIK3CA;CREB1;HRAS;IGF1R
15,prerank,MSigDB_Hallmark_2020__UV Response Dn,-0.6536633397468229,-1.851498622284978,0.0064516129032258064,0.007473122978760598,0.032,15/35,11.04%,ADD3;ATP2B1;PTEN;SYNE1;CITED2;NR3C1;PRKAR2B;CDKN1B;CELF2;YTHDC1;MAPK14;PRDM2;PIK3CD;ATRX;SMAD7
16,prerank,KEGG_2021_Human__T cell receptor signaling pathway,-0.6516115720643708,-1.8439976014362236,0.0,0.008401157858475967,0.038,15/40,11.55%,PPP3CA;FOS;PAK2;SOS2;AKT1;JUN;TNF;VAV3;NFKBIA;GSK3B;KRAS;PIK3CB;MAPK14;PIK3CD;MAPK1
17,prerank,KEGG_2021_Human__Wnt signaling pathway,-0.6993581082895447,-1.8315137698384827,0.005405405405405406,0.010148685526711923,0.047,16/30,19.67%,PPP3CA;TPTEP2-CSNK1E;TBL1Y;JUN;PRKCB;FRAT2;TBL1XR1;FRAT1;GSK3B;PLCB2;SIAH1;SENP2;PPP3R1;ROCK2;CTNNB1;EP300
18,prerank,KEGG_2021_Human__Choline metabolism in cancer,-0.6482727775144463,-1.8300594374428427,0.0,0.009789354077440785,0.048,12/36,11.55%,FOS;DGKH;SOS2;WASF2;AKT1;JUN;PRKCB;KRAS;PIK3CB;PIK3CD;PIP5K1B;MAPK1
19,prerank,KEGG_2021_Human__GnRH secretion,-0.7427258509721034,-1.821092930899689,0.0,0.010296302770736825,0.053,9/18,11.55%,GNAQ;AKT1;PRKCB;KRAS;PLCB2;PIK3CB;PIK3CD;SPP1;MAPK1
20,prerank,KEGG_2021_Human__Chemical carcinogenesis,-0.6005170353569548,-1.8135763541808767,0.0,0.010754970636099908,0.058,18/59,9.96%,FOS;PTGS2;CREB5;SOS2;KPNA1;VEGFA;AKT1;JUN;PRKCB;JAK2;GNAI3;GNAI2;KRAS;KPNA4;PIK3CB;BCL6;HSP90AB1;PIK3CD
21,prerank,KEGG_2021_Human__Calcium signaling pathway,-0.6966325922605918,-1.8069068281562117,0.0,0.011171941422793622,0.063,8/26,7.39%,PPP3CA;ATP2B1;GNAQ;VEGFA;PRKCB;ORAI1;CALM1;PLCB2
22,prerank,KEGG_2021_Human__Relaxin signaling pathway,-0.6292797146509419,-1.7930478865051243,0.008620689655172414,0.0121302865742201,0.071,18/45,12.97%,FOS;CREB5;SOS2;VEGFA;AKT1;JUN;NFKBIA;GNAI3;GNAI2;KRAS;PLCB2;PIK3CB;MAPK14;GNB1;PIK3CD;GNG11;MAPK1;GNA15
23,prerank,KEGG_2021_Human__Circadian entrainment,-0.7580410338659191,-1.789550827300426,0.0,0.012040031465780964,0.074,10/18,11.55%,FOS;GNAQ;PRKCB;GNAI3;GNAI2;CALM1;PLCB2;GNB1;GNG11;MAPK1
24,prerank,KEGG_2021_Human__Melanogenesis,-0.6944681244960055,-1.777199613462986,0.0,0.013285551962241064,0.081,9/21,11.55%,GNAQ;PRKCB;GNAI3;GSK3B;GNAI2;KRAS;CALM1;PLCB2;MAPK1
25,prerank,KEGG_2021_Human__Cushing syndrome,-0.6728715832941461,-1.7686364478772647,0.004830917874396135,0.014946245957521196,0.095,13/29,13.68%,NR4A1;E2F2;CREB5;GNAQ;GNAI3;ORAI1;GSK3B;GNAI2;CDKN1B;PLCB2;MAPK1;KMT2A;BRAF
26,prerank,MSigDB_Hallmark_2020__Mitotic Spindle,-0.5746895672391086,-1.7661839838335336,0.0,0.014761724402490071,0.097,32/67,19.20%,ROCK1;RALBP1;CCDC88A;WASF2;RANBP9;EZR;FGD4;HOOK3;MID1IP1;FLNA;CLIP1;SSH2;MYH9;MARCKS;PREX1;SPTAN1;ARHGAP4;PPP4R2;ARL8A;VCL;TUBA4A;ARFGEF1;ARHGEF2;ARHGAP27;KNTC1;SPTBN1;NUMA1;ARAP3;KIF5B;ARF6;KIF1B;AKAP13
27,prerank,KEGG_2021_Human__Insulin resistance,-0.5943285429423384,-1.7425560736997021,0.013793103448275862,0.018623496947070065,0.125,10/41,9.96%,PTEN;CREB5;AKT1;TNF;PRKCB;NFKBIA;GSK3B;PPP1CB;PIK3CB;PIK3CD
28,prerank,KEGG_2021_Human__MAPK signaling pathway,-0.535345318577198,-1.7377036159288641,0.0,0.01855396049899183,0.129,29/88,14.30%,PPP3CA;FOS;PAK2;NR4A1;SOS2;VEGFA;JUND;AKT1;JUN;TNF;PRKCB;DDIT3;MEF2C;KRAS;FLNA;DUSP7;MAPKAPK2;DUSP6;MAPK14;MAP3K5;PPM1A;MAP3K2;MAPK1;DUSP5;MAP2K3;MAX;BRAF;RASGRP4;PTPN7
29,prerank,KEGG_2021_Human__Serotonergic synapse,-0.6825630848218782,-1.7273034307932282,0.0,0.019485476211286892,0.137,11/22,13.68%,PTGS2;GNAQ;PRKCB;GNAI3;GNAI2;KRAS;PLCB2;GNB1;GNG11;MAPK1;BRAF
30,prerank,KEGG_2021_Human__ErbB signaling pathway,-0.6458490500590588,-1.7252672456232345,0.0111731843575419,0.019285478654866055,0.14,13/33,13.68%,PAK2;SOS2;AKT1;JUN;PRKCB;GSK3B;KRAS;CDKN1B;CBL;PIK3CB;PIK3CD;MAPK1;BRAF
31,prerank,KEGG_2021_Human__VEGF signaling pathway,-0.6654459059061196,-1.7252204508999578,0.008771929824561403,0.018682807446901494,0.14,11/28,11.55%,PPP3CA;PTGS2;VEGFA;AKT1;PRKCB;KRAS;PIK3CB;MAPKAPK2;MAPK14;PIK3CD;MAPK1
32,prerank,MSigDB_Hallmark_2020__Interferon Alpha Response,0.9485689385402577,1.7190381116369455,0.0,0.0,0.0,50/64,5.11%,RTP4;NMI;IFIT3;MX1;UBE2L6;B2M;IRF7;PSME1;IRF9;PARP9;RSAD2;SP110;LY6E;PSMB8;IFI35;CMPK2;HERC6;SAMD9;EPSTI1;ISG15;TRAFD1;PARP14;EIF2AK2;IFIT2;IFI44L;PSMB9;TMEM140;TAP1;PSMA3;HELZ2;BST2;STAT2;UBA7;TRIM21;IFITM3;PSME2;WARS1;DHX58;PARP12;DDX60;ADAR;TDRD7;OGFR;IRF1;LGALS3BP;SAMD9L;TRIM25;IFITM2;TRIM26;SELL
33,prerank,KEGG_2021_Human__Long-term potentiation,-0.6699658085320428,-1.7123324734513434,0.004219409282700422,0.020733512910770142,0.157,13/25,21.10%,PPP3CA;GNAQ;PRKCB;KRAS;CALM1;PPP1CB;PLCB2;MAPK1;BRAF;PPP3R1;EP300;MAP2K2;RPS6KA3
34,prerank,KEGG_2021_Human__Progesterone-mediated oocyte maturation,-0.6397159933286363,-1.6891055685401175,0.004273504273504274,0.025691912985804408,0.192,15/25,24.54%,AKT1;GNAI3;GNAI2;KRAS;PIK3CB;MAPK14;HSP90AB1;PIK3CD;MAPK1;BRAF;CPEB4;RPS6KA3;PIK3CA;STK10;IGF1R
35,prerank,KEGG_2021_Human__Glucagon signaling pathway,-0.635181418276696,-1.6870483660665276,0.013636363636363636,0.025811929526639778,0.198,8/30,7.75%,PPP3CA;CREB5;GNAQ;AKT1;SIRT1;CALM1;PLCB2;PGAM4
36,prerank,KEGG_2021_Human__Gap junction,-0.656438579527477,-1.681696473609476,0.0,0.026202060814419875,0.205,11/22,11.55%,SOS2;GNAQ;PRKCB;GNAI3;TUBB4B;GNAI2;KRAS;PLCB2;TUBB3;MAP3K2;MAPK1
37,prerank,KEGG_2021_Human__B cell receptor signaling pathway,-0.6011832026458627,-1.676691367819274,0.006896551724137931,0.027827845326315735,0.221,13/40,11.55%,PPP3CA;FOS;SOS2;AKT1;JUN;VAV3;PRKCB;NFKBIA;GSK3B;KRAS;PIK3CB;PIK3CD;MAPK1
38,prerank,MSigDB_Hallmark_2020__Interferon Gamma Response,0.9221629739983886,1.670187641727335,0.0,0.0006009705674664583,0.002,62/119,4.88%,RTP4;NMI;IFIT3;MX1;UBE2L6;B2M;IRF7;PSME1;IRF9;ZBP1;RSAD2;SP110;LY6E;PSMB8;DDX58;IFI35;CMPK2;HERC6;EPSTI1;ISG15;STAT1;TRAFD1;PARP14;EIF2AK2;IFIT2;IFI44L;PSMB9;RNF213;SAMHD1;TAP1;PSMA3;PSMB10;HELZ2;BST2;STAT2;TNFSF10;NAMPT;TRIM21;IFITM3;IL15RA;PSME2;WARS1;DHX58;CCL5;NOD1;PARP12;DDX60;CD274;ADAR;TDRD7;OGFR;IRF1;LGALS3BP;FAS;GZMA;SAMD9L;TRIM25;PSMA2;IFITM2;IFIT1;CFB;TRIM26
39,prerank,KEGG_2021_Human__IL-17 signaling pathway,-0.5937428322787053,-1.668188628037832,0.005494505494505495,0.028756227602482302,0.231,12/30,11.55%,FOS;PTGS2;JUND;CXCL2;JUN;TNF;NFKBIA;GSK3B;MAPK14;HSP90AB1;FOSB;MAPK1
40,prerank,KEGG_2021_Human__Alcoholism,-0.6352734208759208,-1.6662522101895194,0.00558659217877095,0.028359543611706884,0.233,12/32,13.68%,CREB5;SOS2;GNAI3;GNAI2;KRAS;CALM1;PPP1CB;GNB1;FOSB;GNG11;MAPK1;BRAF
41,prerank,KEGG_2021_Human__Vascular smooth muscle contraction,-0.6171527582397079,-1.6623886524134839,0.014285714285714285,0.0287300061183463,0.238,12/28,16.94%,ROCK1;PPP1R12A;GNAQ;PRKCB;CALM1;PPP1CB;PLCB2;MYH9;MAPK1;BRAF;PPP1R12C;ROCK2
42,prerank,KEGG_2021_Human__Phosphatidylinositol signaling system,-0.6132449008324479,-1.6567208359757444,0.004830917874396135,0.029568454062304805,0.25,10/29,11.71%,DGKH;PTEN;PRKCB;SACM1L;CALM1;PLCB2;PIK3CB;PIK3CD;PIP5K1B;PIP4K2A
43,prerank,KEGG_2021_Human__Platelet activation,-0.5524022392233612,-1.6530022810502412,0.014598540145985401,0.029418007916390924,0.254,14/44,11.55%,TLN1;ROCK1;PPP1R12A;GNAQ;AKT1;GNAI3;ORAI1;GNAI2;PPP1CB;PLCB2;PIK3CB;MAPK14;PIK3CD;MAPK1
44,prerank,KEGG_2021_Human__Apelin signaling pathway,-0.5713155012894553,-1.636682741000609,0.0,0.03360008781148176,0.291,13/42,11.55%,GNAQ;AKT1;GNAI3;MEF2C;MEF2A;GNAI2;KRAS;CALM1;PLCB2;GNB1;SPP1;GNG11;MAPK1
45,prerank,KEGG_2021_Human__GnRH signaling pathway,-0.6088341776385654,-1.6339061204530945,0.014218009478672985,0.033289365996297206,0.292,11/28,12.84%,SOS2;GNAQ;JUN;PRKCB;KRAS;CALM1;PLCB2;MAPK14;MAP3K2;MAPK1;MAP2K3
46,prerank,KEGG_2021_Human__Yersinia infection,-0.49956926268564406,-1.6207085416585771,0.0,0.03557575581000107,0.31,21/68,13.63%,ROCK1;FOS;GNAQ;WASF2;AKT1;ACTR2;JUN;TNF;VAV3;ITGA4;NLRP3;NFKBIA;GSK3B;WIPF1;PIK3CB;MAPK14;PIK3CD;PIP5K1B;MAPK1;MAP2K3;SKAP2
47,prerank,KEGG_2021_Human__Sphingolipid signaling pathway,-0.5238036917910296,-1.6135224476365115,0.01904761904761905,0.03769053328418388,0.331,22/54,16.97%,ROCK1;PTEN;GNAQ;AKT1;TNF;PRKCB;GNAI3;GNAI2;KRAS;PLCB2;PIK3CB;CERS2;MAPK14;SGPL1;PIK3CD;MAP3K5;MAPK1;ABCC1;SGPP1;PPP2R5A;ROCK2;S1PR4
48,prerank,KEGG_2021_Human__PI3K-Akt signaling pathway,-0.4595278957462174,-1.6061148929389388,0.0,0.038937974102100134,0.347,23/94,11.55%,NR4A1;PTEN;CREB5;SOS2;VEGFA;AKT1;ITGA4;JAK1;JAK2;OSM;GSK3B;KRAS;SGK1;CDKN1B;PIK3CB;GNB1;HSP90AB1;PIK3CD;SPP1;GNG11;MCL1;STK11;MAPK1
49,prerank,KEGG_2021_Human__Leukocyte transendothelial migration,-0.5374201343772756,-1.5993801070549398,0.021897810218978103,0.04047941613495324,0.365,13/43,9.96%,ROCK1;EZR;ACTN1;VAV3;ITGA4;PRKCB;MSN;GNAI3;ITGAM;GNAI2;PIK3CB;MAPK14;PIK3CD
50,prerank,KEGG_2021_Human__Rap1 signaling pathway,-0.5161046422063603,-1.5973038251502387,0.0,0.04026335645699588,0.368,18/62,13.68%,TLN1;GNAQ;VEGFA;AKT1;VAV3;PRKCB;GNAI3;ITGAM;GNAI2;KRAS;CALM1;PLCB2;PIK3CB;MAPK14;PIK3CD;MAPK1;MAP2K3;BRAF
51,prerank,KEGG_2021_Human__Long-term depression,-0.638192417309795,-1.5971066203334596,0.01556420233463035,0.03952451708766717,0.369,8/20,13.68%,GNAQ;PRKCB;GNAI3;GNAI2;KRAS;PLCB2;MAPK1;BRAF
52,prerank,KEGG_2021_Human__Gastric acid secretion,-0.6949011390709803,-1.5855298609758959,0.023026315789473683,0.042657041839548514,0.398,7/15,7.39%,GNAQ;EZR;PRKCB;GNAI3;GNAI2;CALM1;PLCB2
53,prerank,KEGG_2021_Human__Regulation of actin cytoskeleton,-0.4864600923518185,-1.5841714935295053,0.0,0.042219951187698765,0.4,35/78,21.18%,ROCK1;PAK2;PPP1R12A;SOS2;WASF2;ACTR2;EZR;ACTN1;VAV3;ITGA4;MSN;ITGAM;KRAS;PPP1CB;PIK3CB;PIK3CD;PIP5K1B;SSH2;MYH9;MAPK1;PIP4K2A;BRAF;IQGAP2;VCL;DIAPH1;PPP1R12C;ROCK2;ITGAX;PAK1;IQGAP1;RDX;ITGB2;ACTB;MAP2K2;ARPC2
54,prerank,MSigDB_Hallmark_2020__Estrogen Response Early,-0.5746633689637518,-1.5769076633777543,0.017045454545454544,0.04418072704424504,0.412,6/36,4.65%,ADD3;SVIL;FOS;KLF10;TOB1;JAK2
55,prerank,KEGG_2021_Human__Axon guidance,-0.5607427854688323,-1.5732435975775008,0.0189873417721519,0.04471572350254284,0.419,12/38,11.55%,PPP3CA;ROCK1;PAK2;GNAI3;GSK3B;GNAI2;KRAS;PIK3CB;PLXNC1;PIK3CD;SSH2;MAPK1
56,prerank,KEGG_2021_Human__mTOR signaling pathway,-0.515522031545294,-1.5619967393864607,0.009345794392523364,0.04873382015240244,0.45,17/54,13.68%,PTEN;SOS2;AKT1;TNF;PRKCB;ULK2;GSK3B;KRAS;SGK1;PIK3CB;CLIP1;PIK3CD;CAB39;STK11;MAPK1;DDIT4;BRAF
57,prerank,KEGG_2021_Human__Cytosolic DNA-sensing pathway,0.8984912358794567,1.546555771344174,0.013793103448275862,0.29868237203082976,0.581,7/18,5.85%,IRF7;ZBP1;DDX58;CCL5;ADAR;STING1;CXCL10
58,prerank,KEGG_2021_Human__Proteasome,0.868312894212175,1.5429103343172086,0.0035252643948296123,0.24564671945191485,0.611,8/37,4.65%,PSME1;PSMB8;PSMB9;PSMA3;PSMB10;PSME2;PSMF1;PSMA2
59,prerank,KEGG_2021_Human__Influenza A,0.8419919205042369,1.534570860633077,0.0032085561497326204,0.24014783875959678,0.666,18/67,5.98%,MX1;IRF7;IRF9;RSAD2;DDX58;STAT1;EIF2AK2;BAK1;STAT2;TNFSF10;CCL5;ADAR;CALCOCO2;FAS;TRIM25;BID;CXCL10;RNASEL
60,prerank,KEGG_2021_Human__Insulin signaling pathway,-0.5110821036969764,-1.5324321681498607,0.040268456375838924,0.06025946782873625,0.516,15/49,14.04%,SOS2;AKT1;PRKAR2B;GSK3B;KRAS;CALM1;PPP1CB;CBL;PIK3CB;PIK3CD;MAPK1;FLOT2;FLOT1;BRAF;PTPN1
61,prerank,KEGG_2021_Human__Hepatitis C,0.8402751749840361,1.527896311881199,0.006430868167202572,0.23317658017698584,0.708,14/65,5.98%,MX1;IRF7;IRF9;RSAD2;DDX58;STAT1;EIF2AK2;BAK1;STAT2;FAS;IFIT1;BID;CXCL10;RNASEL
62,prerank,KEGG_2021_Human__Herpes simplex virus 1 infection,0.8474074243218068,1.5261803308434623,0.0010638297872340426,0.2077641104669756,0.72,18/70,6.32%,B2M;IRF7;IRF9;DDX58;STAT1;EIF2AK2;BAK1;TAP1;BST2;STAT2;CCL5;TAP2;TNFRSF14;FAS;BID;STING1;RNASEL;SRC
63,prerank,KEGG_2021_Human__Antigen processing and presentation,0.8688097998184089,1.5239452994463836,0.03679369250985545,0.19140912573806698,0.735,6/23,4.42%,B2M;PSME1;TAP1;PSME2;TAP2;CTSS
64,prerank,MSigDB_Hallmark_2020__Fatty Acid Metabolism,0.8654133207286592,1.5236925506164987,0.010514018691588784,0.1708091901754667,0.737,2/41,0.39%,UBE2L6;PSME1
65,prerank,KEGG_2021_Human__Amoebiasis,-0.5558906948013949,-1.5205803319045372,0.022222222222222223,0.0654371704105119,0.547,18/32,23.75%,GNAQ;CXCL2;TNF;ACTN1;PRKCB;ITGAM;PLCB2;PIK3CB;PIK3CD;GNA15;VCL;TLR4;IL12A;ITGB2;CXCL1;RAB5A;PIK3CA;IL1B
66,prerank,KEGG_2021_Human__Proteoglycans in cancer,-0.47333579888148125,-1.5122474804065236,0.0,0.06803118849630338,0.565,32/72,20.74%,ROCK1;PPP1R12A;SOS2;VEGFA;AKT1;TNF;EZR;VAV3;PRKCB;MSN;KRAS;PPP1CB;CBL;FLNA;PIK3CB;MAPK14;PIK3CD;MAPK1;BRAF;DDX5;MDM2;MMP9;PPP1R12C;ROCK2;EIF4B;PAK1;TLR4;IQGAP1;RDX;CTNNB1;ACTB;MAP2K2
67,prerank,KEGG_2021_Human__Measles,0.8416778339628791,1.5053851102132243,0.008695652173913044,0.2176715395363512,0.824,10/56,4.16%,MX1;IRF7;IRF9;DDX58;STAT1;EIF2AK2;BAK1;STAT2;ADAR;FAS
68,prerank,KEGG_2021_Human__MicroRNAs in cancer,-0.4777285511073134,-1.5019035804580287,0.012345679012345678,0.07273276752209937,0.585,27/59,16.17%,ROCK1;PTGS2;E2F2;PTEN;SOS2;VEGFA;CCNG1;EZR;PRKCB;SIRT1;KRAS;CDKN1B;PIK3CB;FOXP1;PIK3CD;VIM;MCL1;MAPK1;ZEB2;NOTCH1;MARCKS;DDIT4;ABCC1;HNRNPK;HMOX1;MDM2;MMP9
69,prerank,KEGG_2021_Human__Epstein-Barr virus infection,0.8269685331628485,1.4941313506699414,0.003131524008350731,0.2412077323058558,0.88,17/86,6.78%,B2M;IRF7;IRF9;DDX58;ISG15;STAT1;EIF2AK2;BAK1;TAP1;STAT2;TAP2;FAS;BID;NFKB2;CXCL10;RELB;ICAM1
70,prerank,MSigDB_Hallmark_2020__Inflammatory Response,0.8080865324216349,1.483564744488439,0.007446808510638298,0.2635756747146642,0.915,16/74,6.78%,RTP4;NMI;IRF7;LY6E;EIF2AK2;BST2;TNFSF10;NAMPT;IL15RA;CCL5;IRF1;SELL;LCP2;CXCL10;EBI3;ICAM1
71,prerank,KEGG_2021_Human__Ras signaling pathway,-0.49911954680732823,-1.466043220187376,0.0,0.09128281327389798,0.668,13/63,11.55%,PAK2;RALBP1;SOS2;VEGFA;AKT1;PRKCB;KRAS;CALM1;PIK3CB;GNB1;PIK3CD;GNG11;MAPK1
72,prerank,KEGG_2021_Human__RIG-I-like receptor signaling pathway,0.8389857013753748,1.4648843299242593,0.048327137546468404,0.321889081636073,0.961,7/27,5.85%,IRF7;DDX58;ISG15;DHX58;TRIM25;STING1;CXCL10
73,prerank,KEGG_2021_Human__Adrenergic signaling in cardiomyocytes,-0.5092318335089727,-1.4602831293684264,0.05555555555555555,0.09381559848746455,0.679,10/41,9.22%,ATP2B1;CREB5;GNAQ;AKT1;GNAI3;GNAI2;CALM1;PPP1CB;PLCB2;MAPK14
74,prerank,KEGG_2021_Human__Necroptosis,0.8049383205168316,1.4581874979441576,0.04189636163175303,0.32954650331714286,0.972,11/51,6.93%,IRF9;ZBP1;STAT1;EIF2AK2;STAT2;TNFSF10;FAS;MLKL;BID;CHMP5;RNF31
75,prerank,KEGG_2021_Human__Neurotrophin signaling pathway,-0.48681638064386484,-1.4581479309252856,0.0392156862745098,0.09332028837993521,0.682,14/54,11.55%,SOS2;AKT1;JUN;NFKBIA;GSK3B;KRAS;CALM1;SH2B3;PIK3CB;MAPKAPK2;MAPK14;PIK3CD;MAP3K5;MAPK1
76,prerank,MSigDB_Hallmark_2020__TGF-beta Signaling,-0.5584874005269631,-1.4412241694505559,0.0860655737704918,0.10233038237583295,0.717,6/25,11.04%,KLF10;JUNB;PPP1R15A;ARID4B;PPM1A;SMAD7
77,prerank,KEGG_2021_Human__Longevity regulating pathway,-0.5094554447194081,-1.429126830731752,0.047619047619047616,0.10955390700113626,0.749,16/36,24.54%,CREB5;AKT1;RB1CC1;SIRT1;KRAS;PIK3CB;PIK3CD;STK11;APPL1;ADIPOR1;FOXO3;IRS2;PIK3CA;CREB1;HRAS;IGF1R
78,prerank,KEGG_2021_Human__Signaling pathways regulating pluripotency of stem cells,-0.5221152411214807,-1.4204568106758924,0.08982035928143713,0.113284879616494,0.765,18/32,26.57%,AKT1;JAK1;JAK2;GSK3B;KRAS;PIK3CB;MAPK14;PIK3CD;MAPK1;REST;CTNNB1;MAP2K2;PIK3CA;ID3;HRAS;IGF1R;ID1;SKIL
79,prerank,KEGG_2021_Human__Lysine degradation,-0.5883943419344541,-1.4072370876795508,0.07169811320754717,0.12037515262757811,0.793,8/17,18.49%,COLGALT1;ALDH2;KMT2C;PRDM2;KMT2A;NSD3;KMT2E;KMT5B
80,prerank,MSigDB_Hallmark_2020__IL-6/JAK/STAT3 Signaling,0.7894409321040258,1.3982462235616047,0.0667420814479638,0.6131502376337785,0.996,13/47,9.17%,IRF9;STAT1;BAK1;STAT2;IL15RA;IRF1;FAS;CXCL10;SOCS1;EBI3;LTB;CD38;TNFRSF1A
81,prerank,KEGG_2021_Human__Renal cell carcinoma,-0.48366271307088304,-1.3973250510205564,0.06382978723404255,0.12546914931504524,0.812,10/41,13.68%,PAK2;SOS2;VEGFA;AKT1;JUN;KRAS;PIK3CB;PIK3CD;MAPK1;BRAF
82,prerank,KEGG_2021_Human__Salivary secretion,-0.5884285949952854,-1.3925604768155524,0.10197368421052631,0.1267988709337419,0.823,5/16,7.39%,ATP2B1;GNAQ;PRKCB;CALM1;PLCB2
83,prerank,MSigDB_Hallmark_2020__Allograft Rejection,0.7679897434462638,1.3912457576897723,0.024185068349106203,0.6116002343785213,0.998,18/81,7.75%,B2M;IRF7;STAT1;TAP1;PSMB10;WARS1;CAPG;CCL5;TAP2;FAS;GZMA;CTSS;LCP2;RARS1;SOCS1;ICAM1;GPR65;LTB
84,prerank,MSigDB_Hallmark_2020__Estrogen Response Late,-0.4850374467572372,-1.3715544362556347,0.04929577464788732,0.14070169704938634,0.862,9/40,8.37%,ADD3;FOS;ZFP36;TOB1;JAK1;JAK2;PRKAR2B;SGK1;DNAJC1
85,prerank,KEGG_2021_Human__Bladder cancer,-0.5624282521140901,-1.3666557993566817,0.13636363636363635,0.14315182239314747,0.871,8/17,16.17%,E2F2;VEGFA;KRAS;MAPK1;DAPK1;BRAF;MDM2;MMP9
86,prerank,KEGG_2021_Human__Acute myeloid leukemia,-0.48913164362435385,-1.3402819666504577,0.096045197740113,0.16213987007439268,0.901,10/31,13.68%,SOS2;AKT1;ITGAM;KRAS;PIK3CB;DUSP6;PIK3CD;MAPK1;RARA;BRAF
87,prerank,KEGG_2021_Human__NOD-like receptor signaling pathway,0.7436417526025767,1.3368798200094736,0.10548523206751055,0.9060161572704625,1.0,13/67,7.83%,IRF7;IRF9;STAT1;STAT2;NAMPT;CCL5;NOD1;NLRC4;STING1;RNASEL;RNF31;GSDMD;TRPM2
88,prerank,KEGG_2021_Human__Inflammatory mediator regulation of TRP channels,-0.525754243115311,-1.3302618991435133,0.13333333333333333,0.16925239635230022,0.912,9/23,12.84%,GNAQ;PRKCB;CALM1;PPP1CB;PLCB2;PIK3CB;MAPK14;PIK3CD;MAP2K3
89,prerank,KEGG_2021_Human__Viral carcinogenesis,0.7339008272456276,1.3291335462134084,0.09538784067085954,0.9042603805145311,1.0,4/75,1.69%,IRF7;IRF9;EIF2AK2;BAK1
90,prerank,KEGG_2021_Human__Coronavirus disease,0.7192205081787809,1.31723995318696,0.0539714867617108,0.9270761753916786,1.0,18/126,8.11%,MX1;IRF9;DDX58;ISG15;STAT1;EIF2AK2;STAT2;C4A;ADAR;RPL24;RPS24;CFB;STING1;CXCL10;RPL11;RPL13;RPL26;RPL35
91,prerank,KEGG_2021_Human__JAK-STAT signaling pathway,0.7463064979660123,1.3132372444407097,0.15552995391705068,0.9047611893207531,1.0,4/42,2.72%,IRF9;STAT1;STAT2;IL15RA
92,prerank,KEGG_2021_Human__Fc epsilon RI signaling pathway,-0.49821572092780936,-1.3091471020076806,0.12562814070351758,0.18586123207450253,0.928,10/30,12.84%,SOS2;AKT1;TNF;VAV3;KRAS;PIK3CB;MAPK14;PIK3CD;MAPK1;MAP2K3
93,prerank,KEGG_2021_Human__Human papillomavirus infection,0.7094836758253249,1.3032695312712452,0.08932238193018481,0.9169093800773965,1.0,11/103,5.39%,MX1;IRF9;ISG15;STAT1;EIF2AK2;BAK1;STAT2;IRF1;FAS;TCIRG1;ITGB7
94,prerank,KEGG_2021_Human__Pancreatic secretion,-0.5417227342307535,-1.2939952003646342,0.16721311475409836,0.19690444749443087,0.94,4/16,7.39%,ATP2B1;GNAQ;PRKCB;PLCB2
95,prerank,KEGG_2021_Human__Oocyte meiosis,-0.4637203826421618,-1.2938525623427422,0.12440191387559808,0.1944119103807942,0.94,8/34,16.77%,PPP3CA;SLK;CALM1;PPP1CB;MAPK14;MAPK1;PPP3R1;PPP2R5A
96,prerank,KEGG_2021_Human__Adipocytokine signaling pathway,-0.48828464027446805,-1.285196934307356,0.1350210970464135,0.2010750808495761,0.946,4/24,4.78%,AKT1;TNF;JAK2;NFKBIA
97,prerank,KEGG_2021_Human__Purine metabolism,0.7309097893496292,1.275281429453047,0.2717536813922356,1.0,1.0,6/18,15.20%,NT5C3A;XDH;ITPA;NUDT9;PDE4B;PKM
98,prerank,MSigDB_Hallmark_2020__DNA Repair,0.704287245048931,1.2698391703457745,0.2092238470191226,1.0,1.0,13/50,13.89%,CMPK2;NT5C3A;CDA;VPS28;ITPA;MPC2;SUPT4H1;EDF1;NUDT9;HCLS1;PDE4B;BCAP31;SEC61A1
99,prerank,KEGG_2021_Human__Notch signaling pathway,0.7356532153574298,1.2696406280313257,0.24370860927152319,0.9835884954201035,1.0,1/20,0.87%,DTX3L
100,prerank,KEGG_2021_Human__Glycerophospholipid metabolism,-0.5039477864804089,-1.2638655726387793,0.1694915254237288,0.2219722415509497,0.957,3/22,5.13%,DGKH;GPD2;PLD3
101,prerank,KEGG_2021_Human__TGF-beta signaling pathway,-0.48450924340923796,-1.2622578266958238,0.1598360655737705,0.2204464823991089,0.958,4/24,11.55%,ROCK1;TNF;SMAD7;MAPK1
102,prerank,KEGG_2021_Human__Toll-like receptor signaling pathway,0.7178114894368657,1.259188282655608,0.21305841924398625,0.9986207725476643,1.0,4/40,2.95%,IRF7;STAT1;CCL5;LY96
103,prerank,KEGG_2021_Human__Inositol phosphate metabolism,-0.49906424484752593,-1.25774212745933,0.1829787234042553,0.2230375099990153,0.958,9/24,17.95%,PTEN;SACM1L;PLCB2;PIK3CB;PIK3CD;PIP5K1B;PIP4K2A;PIK3CG;PI4K2A
104,prerank,MSigDB_Hallmark_2020__Androgen Response,0.7072828797785738,1.2443790197936573,0.24195470798569726,1.0,1.0,3/34,5.62%,B2M;SELENOP;TMEM50A
105,prerank,KEGG_2021_Human__Ubiquitin mediated proteolysis,0.681456595955587,1.2367771414084872,0.22466960352422907,1.0,1.0,6/57,8.14%,UBE2L6;UBA7;ELOB;UBE2L3;SOCS1;UBE2F
106,prerank,KEGG_2021_Human__Central carbon metabolism in cancer,-0.47123349596616215,-1.2339450319651628,0.17083333333333334,0.24661305829909974,0.968,8/25,14.79%,PTEN;AKT1;KRAS;PGAM4;PIK3CB;PIK3CD;MAPK1;LDHB
107,prerank,KEGG_2021_Human__Fc gamma R-mediated phagocytosis,-0.4093259293163722,-1.2210553503286934,0.15625,0.2593963015837561,0.975,16/45,21.18%,WASF2;AKT1;ACTR2;VAV3;PRKCB;PIK3CB;PIK3CD;PIP5K1B;MAPK1;MARCKS;FCGR2B;PAK1;PTPRC;ARF6;ASAP1;ARPC2
108,prerank,KEGG_2021_Human__Phospholipase D signaling pathway,-0.4084017541356613,-1.2204473273767293,0.18796992481203006,0.2570430266840908,0.976,9/44,11.55%,DGKH;SOS2;AKT1;KRAS;PLCB2;PIK3CB;PIK3CD;PIP5K1B;MAPK1
109,prerank,KEGG_2021_Human__Chagas disease,-0.4114771969756175,-1.2157502353495235,0.14782608695652175,0.25994863116481304,0.979,14/45,12.97%,FOS;GNAQ;AKT1;JUN;TNF;NFKBIA;GNAI3;GNAI2;PLCB2;PIK3CB;MAPK14;PIK3CD;MAPK1;GNA15
110,prerank,"KEGG_2021_Human__Growth hormone synthesis, secretion and action",-0.42061831273069217,-1.208796965852254,0.21428571428571427,0.26590874091092603,0.983,16/41,9.96%,FOS;CREB5;SOS2;GNAQ;AKT1;JUNB;PRKCB;JAK2;GNAI3;GSK3B;GNAI2;KRAS;PLCB2;PIK3CB;MAPK14;PIK3CD
111,prerank,KEGG_2021_Human__Breast cancer,-0.4154918697368666,-1.2086888162291447,0.17985611510791366,0.2627804027825622,0.983,15/40,13.68%,FOS;E2F2;PTEN;SOS2;AKT1;JUN;FRAT2;FRAT1;GSK3B;KRAS;PIK3CB;PIK3CD;MAPK1;NOTCH1;BRAF
112,prerank,KEGG_2021_Human__C-type lectin receptor signaling pathway,0.6529599424946887,1.1774753397448763,0.3170731707317073,1.0,1.0,9/50,6.42%,IRF9;STAT1;STAT2;IRF1;CLEC4E;NFKB2;FCER1G;SRC;RELB
113,prerank,KEGG_2021_Human__FoxO signaling pathway,-0.4025367312288992,-1.1771299555052872,0.2222222222222222,0.29749594989867123,0.988,15/52,11.55%,PTEN;SOS2;TPTEP2-CSNK1E;AKT1;CCNG2;SIRT1;KRAS;SGK1;CDKN1B;PIK3CB;MAPK14;BCL6;PIK3CD;STK11;MAPK1
114,prerank,KEGG_2021_Human__Kaposi sarcoma-associated herpesvirus infection,0.6466623111261555,1.1687899252358198,0.29811715481171547,1.0,1.0,10/81,6.78%,IRF7;IRF9;STAT1;EIF2AK2;BAK1;STAT2;FAS;BID;SRC;ICAM1
115,prerank,KEGG_2021_Human__Hepatocellular carcinoma,-0.3712195022078601,-1.1652363091034175,0.22448979591836735,0.3085454912610123,0.99,17/57,13.68%,E2F2;PTEN;SOS2;AKT1;TXNRD1;ARID1B;PRKCB;FRAT2;FRAT1;GSK3B;KRAS;PIK3CB;PIK3CD;PBRM1;MAPK1;ARID1A;BRAF
116,prerank,MSigDB_Hallmark_2020__G2-M Checkpoint,-0.3864082143127221,-1.1647635486017478,0.2524271844660194,0.30560543817689173,0.991,19/53,18.10%,E2F2;FOXN3;LBR;SRSF2;SFPQ;AMD1;CDKN1B;ARID4A;YTHDC1;MAPK14;ATRX;CHMP1A;CUL3;MTF2;MARCKS;PURA;UBE2S;NUMA1;KIF5B
117,prerank,KEGG_2021_Human__Hepatitis B,0.6493356660771075,1.1633644210101075,0.30662393162393164,1.0,1.0,7/67,6.32%,IRF7;DDX58;STAT1;STAT2;FAS;BID;SRC
118,prerank,KEGG_2021_Human__Oxidative phosphorylation,0.6365174056429702,1.1600156756152349,0.3073639274279616,1.0,1.0,32/70,20.41%,NDUFA7;NDUFA13;TCIRG1;COX2;NDUFA12;ATP5MF;NDUFB7;NDUFB9;ATP5MC1;ATP5ME;ATP5F1E;ATP5MC3;NDUFA4;ATP6V1F;ATP5PO;NDUFB11;ATP5PD;COX1;ND1;ND5;NDUFV3;NDUFB3;ND4L;ND4;ATP6V1B2;NDUFA2;ATP5MC2;CYTB;NDUFA6;ATP5F1C;ATP6V0C;NDUFS6
119,prerank,KEGG_2021_Human__RNA degradation,-0.4295417896211386,-1.1581666736170437,0.2634146341463415,0.31075503143140826,0.991,7/28,13.66%,BTG2;CNOT6L;TOB1;PAN3;DDX6;PABPC1;BTG1
120,prerank,KEGG_2021_Human__Fluid shear stress and atherosclerosis,-0.38649010787930455,-1.147039275646732,0.23333333333333334,0.32250677388340176,0.993,13/51,10.01%,FOS;VEGFA;AKT1;JUN;TNF;MEF2C;MEF2A;CALM1;PIK3CB;MAPK14;HSP90AB1;PIK3CD;MAP3K5
121,prerank,KEGG_2021_Human__Inflammatory bowel disease,0.6791800400648912,1.1448772009378831,0.3680649526387009,1.0,1.0,1/18,1.18%,STAT1
122,prerank,KEGG_2021_Human__Viral protein interaction with cytokine and cytokine receptor,0.6556675493834202,1.1441239891917372,0.35,1.0,1.0,9/24,14.63%,TNFSF10;CCL5;TNFRSF14;CXCL10;CXCR2;TNFRSF1A;IL2RG;IL10RA;LTBR
123,prerank,KEGG_2021_Human__Human immunodeficiency virus 1 infection,0.6298819446887569,1.1429187818506856,0.3238095238095238,1.0,1.0,10/79,5.73%,B2M;BAK1;SAMHD1;TAP1;BST2;TAP2;FAS;ELOB;BID;STING1
124,prerank,KEGG_2021_Human__Staphylococcus aureus infection,0.6606194971565231,1.1376052250410456,0.34924965893587995,1.0,1.0,5/19,7.52%,C4A;FPR2;CFB;ICAM1;FCGR3B
125,prerank,KEGG_2021_Human__NF-kappa B signaling pathway,0.634356023881216,1.1363766791965078,0.3695906432748538,1.0,1.0,9/39,9.17%,DDX58;LY96;TRIM25;BCL2A1;NFKB2;RELB;ICAM1;LTB;TNFRSF1A
126,prerank,KEGG_2021_Human__Thyroid cancer,0.6579057787223968,1.1282999809640002,0.3787878787878788,1.0,1.0,1/20,1.69%,BAK1
127,prerank,KEGG_2021_Human__Cytokine-cytokine receptor interaction,0.6243213833091823,1.115473075227826,0.39265212399540755,1.0,1.0,11/50,9.17%,TNFSF10;IL15RA;CCL5;TNFRSF14;FAS;CXCL10;EBI3;IL1RN;LTB;CXCR2;TNFRSF1A
128,prerank,MSigDB_Hallmark_2020__Glycolysis,-0.38009540918238666,-1.1107681630908686,0.3486238532110092,0.3714479734058442,0.997,6/49,2.93%,HSPA5;KIF2A;VEGFA;MXI1;CITED2;UGP2
129,prerank,MSigDB_Hallmark_2020__Complement,0.611715501286727,1.1042735961167613,0.3682008368200837,1.0,1.0,17/81,8.96%,IRF7;PSMB9;CCL5;IRF1;VCPIP1;CDA;GZMA;CTSS;CFB;LCP2;FCER1G;SRC;PLEK;EHD1;USP15;LGALS3;CASP7
130,prerank,KEGG_2021_Human__Sphingolipid metabolism,-0.4811826100266234,-1.1002211995444566,0.32131147540983607,0.3832592924759542,0.997,4/15,9.91%,CERK;ACER3;CERS2;SGPL1
131,prerank,KEGG_2021_Human__Osteoclast differentiation,0.608423777571804,1.098974786719441,0.397170837867247,1.0,1.0,9/58,7.52%,IRF9;STAT1;STAT2;NCF2;LCP2;NFKB2;RELB;SOCS1;FCGR3B
132,prerank,KEGG_2021_Human__Parkinson disease,0.6012368765181513,1.0969734746927984,0.3617021276595745,1.0,1.0,43/126,19.56%,UBE2L6;PSMA3;UBA7;NDUFA7;NDUFA13;PSMA2;UBE2L3;COX2;NDUFA12;NDUFB7;NDUFB9;ATP5MC1;PSMB4;ATP5F1E;ATP5MC3;NDUFA4;ATP5PO;TXN2;PSMA1;NDUFB11;UBB;PSMB3;PSMB2;ATP5PD;COX1;PSMA6;ND1;ND5;PSMD14;NDUFV3;NDUFB3;ND4L;CASP3;UBE2J1;ND4;ATF4;NDUFA2;PSMC5;ATP5MC2;CYTB;PSMC2;NDUFA6;ATP5F1C
133,prerank,KEGG_2021_Human__Tight junction,-0.36451957783436034,-1.0953326225522448,0.3177570093457944,0.3867095608794253,0.997,11/50,14.92%,ROCK1;ACTR2;JUN;EZR;ACTN1;MSN;MAP3K5;MYH9;STK11;TUBA4A;ARHGEF2
134,prerank,MSigDB_Hallmark_2020__Xenobiotic Metabolism,0.6164471275684479,1.0907549858855756,0.4243119266055046,1.0,1.0,10/42,10.47%,PSMB10;CDA;XDH;FAS;CFB;ALAS1;NMT1;TNFRSF1A;ARG1;ID2
135,prerank,MSigDB_Hallmark_2020__Myogenesis,-0.38527108460017284,-1.0844676642439774,0.29411764705882354,0.39888456410037065,0.999,7/36,13.76%,SVIL;CFD;MEF2C;MEF2A;MYH9;NOTCH1;SPTAN1
136,prerank,KEGG_2021_Human__Adherens junction,-0.3926852385762595,-1.0755192126373538,0.3532608695652174,0.40846079888121667,0.999,10/28,20.44%,WASF2;ACTN1;FER;MAPK1;PTPN1;VCL;IQGAP1;CTNNB1;EP300;ACTB
137,prerank,KEGG_2021_Human__AMPK signaling pathway,-0.35653680136446025,-1.0412673844389002,0.37662337662337664,0.4615345395216036,0.999,16/45,24.54%,CREB5;AKT1;SIRT1;PIK3CB;PIK3CD;HMGCR;CAB39;STK11;PPP2R5A;ADIPOR1;FOXO3;IRS2;PIK3CA;CRTC2;CREB1;IGF1R
138,prerank,KEGG_2021_Human__Cell adhesion molecules,0.6122978769108263,1.0399188345563248,0.4686131386861314,1.0,1.0,4/15,6.78%,CD274;SELL;ITGB7;ICAM1
139,prerank,KEGG_2021_Human__Protein export,-0.4348518909806819,-1.025414791850392,0.4144736842105263,0.48341603763639,0.999,2/15,1.69%,HSPA5;SEC11C
140,prerank,KEGG_2021_Human__Gastric cancer,-0.35732590894221283,-1.003547671102657,0.40816326530612246,0.5172214502442879,0.999,11/38,11.55%,E2F2;SOS2;AKT1;FRAT2;FRAT1;GSK3B;KRAS;CDKN1B;PIK3CB;PIK3CD;MAPK1
141,prerank,KEGG_2021_Human__Phagosome,0.5470505961896206,0.9994889012897563,0.5082508250825083,1.0,1.0,13/60,14.53%,TAP1;TAP2;CTSS;NCF2;TCIRG1;SEC61B;FCGR3B;ATP6V1F;LAMP2;FCGR1A;SEC61G;SEC61A1;MARCO
142,prerank,MSigDB_Hallmark_2020__Oxidative Phosphorylation,0.540823342754655,0.9901255818361079,0.5299586776859504,1.0,1.0,38/88,28.81%,NDUFA7;TCIRG1;ALAS1;ATP5MF;NDUFB7;CASP7;ATP5MC1;ATP5ME;FH;ATP5F1E;ATP5MC3;NDUFA4;ATP6V1F;ATP5PO;ATP5PD;HADHA;PDHB;IDH3G;NDUFB3;ETFB;NDUFA2;ATP5MC2;NDUFA6;ATP5F1C;ATP6V0C;NDUFS6;MPC1;ATP6V1D;TOMM22;MGST3;ATP5MG;ATP6V1E1;POLR2F;SDHD;NDUFS8;NDUFA3;SDHB;NDUFS7
143,prerank,KEGG_2021_Human__Glycerolipid metabolism,-0.42955141784330086,-0.9859717443343818,0.4521452145214521,0.5449760254410198,0.999,2/15,4.57%,DGKH;ALDH2
144,prerank,KEGG_2021_Human__Ribosome,0.5394686688277232,0.9852469247424204,0.5320041972717734,1.0,1.0,36/94,23.88%,RPL24;MRPL30;RPS24;RPL11;RPL13;RPL26;RPL35;MRPL36;RPL36;FAU;RPL14;RPS29;MRPL27;RPL7A;RPS15A;RPS23;MRPL3;RPS19;RPL35A;RPL23;RPLP2;RPS16;RPL22;RPL37;RPS18;MRPS18C;RPL18A;RPS5;RPS26;RPL21;RPL3L;RPS6;RPL34;RPL6;RPL13A;RPS27L
145,prerank,MSigDB_Hallmark_2020__heme Metabolism,-0.30889998364152577,-0.9805836390790102,0.46875,0.549357573638668,0.999,20/69,18.69%,BTG2;E2F2;NUDT4;MXI1;NR3C1;KLF3;SLC30A1;SEC14L1;KDM7A;TNRC6B;VEZF1;MARK3;MAP2K3;BACH1;UCP2;BMP2K;FBXO9;ADIPOR1;ATP6V0A1;NEK7
146,prerank,KEGG_2021_Human__Ribosome biogenesis in eukaryotes,0.5727837936769757,0.9682873358281956,0.5263157894736842,1.0,1.0,5/16,16.33%,FCF1;XRN1;EIF6;NOP10;RPP25L
147,prerank,KEGG_2021_Human__Glioma,-0.3674570056945856,-0.9673724846474258,0.5263157894736842,0.5676942661489294,1.0,10/31,11.55%,E2F2;PTEN;SOS2;AKT1;PRKCB;KRAS;CALM1;PIK3CB;PIK3CD;MAPK1
148,prerank,KEGG_2021_Human__Pancreatic cancer,0.5479439284325025,0.9668662564623368,0.5539739027283511,1.0,1.0,2/38,1.69%,STAT1;BAK1
149,prerank,KEGG_2021_Human__Human cytomegalovirus infection,0.5269911965286792,0.966023684882627,0.5841073271413829,1.0,1.0,9/90,6.32%,B2M;BAK1;TAP1;CCL5;TAP2;FAS;BID;STING1;SRC
150,prerank,KEGG_2021_Human__Rheumatoid arthritis,-0.34681167408627633,-0.9649650345697196,0.5,0.5667850918009018,1.0,5/31,3.36%,FOS;VEGFA;CXCL2;JUN;TNF
151,prerank,MSigDB_Hallmark_2020__Unfolded Protein Response,-0.31521096257481535,-0.956402193274612,0.5726495726495726,0.578147235754903,1.0,3/49,1.75%,HSPA5;DNAJC3;VEGFA
152,prerank,KEGG_2021_Human__Cell cycle,-0.34418416811147645,-0.9480267363632997,0.5144508670520231,0.5877259922142363,1.0,4/32,8.11%,E2F2;GSK3B;CDKN1B;STAG2
153,prerank,KEGG_2021_Human__HIF-1 signaling pathway,-0.3175103799001283,-0.9326235744660448,0.5806451612903226,0.6106609062644375,1.0,15/46,20.74%,VEGFA;AKT1;PRKCB;CDKN1B;PIK3CB;PIK3CD;PGK1;MAPK1;LDHB;HMOX1;TLR4;EP300;ARNT;MKNK2;MAP2K2
154,prerank,MSigDB_Hallmark_2020__KRAS Signaling Up,0.5156685517954852,0.9306075379644992,0.605524861878453,1.0,1.0,7/57,5.96%,PSMB8;LY96;CTSS;GLRX;CFB;CXCL10;FCER1G
155,prerank,KEGG_2021_Human__Vibrio cholerae infection,0.5372713868255263,0.9298553917542585,0.6039215686274509,1.0,1.0,10/24,26.83%,TCIRG1;SEC61B;ATP6V1F;SEC61G;SEC61A1;ATP6V1B2;ATP6V0C;ATP6V1D;ATP6V1E1;ACTG1
156,prerank,MSigDB_Hallmark_2020__Epithelial Mesenchymal Transition,-0.3372602401965442,-0.9280374839695779,0.5575757575757576,0.61342276123772,1.0,9/34,10.68%,RHOB;COLGALT1;VEGFA;JUN;ECM1;WIPF1;FLNA;VIM;SPP1
157,prerank,KEGG_2021_Human__Neuroactive ligand-receptor interaction,0.5421942092080427,0.9247019146575091,0.5694050991501416,1.0,1.0,5/17,17.10%,GZMA;FPR2;P2RY2;F2RL2;P2RY13
158,prerank,KEGG_2021_Human__Bacterial invasion of epithelial cells,-0.32309555314480454,-0.921083351026455,0.5837837837837838,0.6213168412995728,1.0,13/35,23.54%,WASF2;ACTR2;CBL;PIK3CB;PIK3CD;VCL;CTNNB1;CLTC;ACTB;ARPC2;PIK3CA;ILK;SHC1
159,prerank,KEGG_2021_Human__Lipid and atherosclerosis,0.5106825972847463,0.917810498311161,0.6495278069254984,1.0,1.0,9/84,6.78%,IRF7;TNFSF10;CCL5;LY96;FAS;NCF2;BID;SRC;ICAM1
160,prerank,KEGG_2021_Human__Synaptic vesicle cycle,0.5266011162011424,0.912102500241883,0.582312925170068,1.0,1.0,10/20,29.27%,TCIRG1;ATP6V1F;AP2S1;ATP6V1B2;ATP6V0C;AP2A2;ATP6V1D;ATP6V1E1;VAMP2;ATP6V1A
161,prerank,KEGG_2021_Human__Hypertrophic cardiomyopathy,-0.3873528711644998,-0.911507300240932,0.5472312703583062,0.6326936586092254,1.0,2/16,3.77%,TNF;ITGA4
162,prerank,KEGG_2021_Human__Pathways of neurodegeneration,0.49823999824343984,0.9035242259293594,0.7127127127127127,1.0,1.0,46/189,16.71%,UBE2L6;BAK1;PSMA3;UBA7;NDUFA7;FAS;NDUFA13;PSMA2;UBE2L3;COX2;BID;GPX1;NDUFA12;NDUFB7;NDUFB9;CASP7;ATP5MC1;GABARAPL2;TNFRSF1A;RAB8A;PSMB4;ATP5F1E;ATP5MC3;NDUFA4;ATP5PO;SOD1;PSMA1;NDUFB11;TBK1;UBB;PSMB3;PSMB2;ATP5PD;COX1;PSMA6;ND1;ND5;PSMD14;NDUFV3;DCTN5;TANK;NDUFB3;ND4L;CASP3;UBE2J1;ND4
163,prerank,KEGG_2021_Human__Apoptosis,0.5015102350265795,0.8953903604722692,0.6547085201793722,1.0,1.0,11/54,10.06%,BAK1;TNFSF10;FAS;CTSS;BCL2A1;BID;LMNB1;CASP7;TNFRSF1A;CTSH;CTSZ
164,prerank,MSigDB_Hallmark_2020__p53 Pathway,0.4905778157665586,0.8898747949900203,0.6677248677248677,1.0,1.0,7/82,6.88%,TRAFD1;BAK1;TAP1;FAS;SOCS1;RALGDS;VAMP8
165,prerank,KEGG_2021_Human__Prolactin signaling pathway,0.5037232642359142,0.8736727678970567,0.638118214716526,1.0,1.0,4/31,6.55%,STAT1;IRF1;SRC;SOCS1
166,prerank,KEGG_2021_Human__Pertussis,0.48468862640509003,0.8588758798239411,0.6489746682750301,1.0,1.0,4/35,3.44%,C4A;LY96;NOD1;IRF1
167,prerank,KEGG_2021_Human__Toxoplasmosis,0.4833925236119474,0.857508938690541,0.6713780918727915,1.0,1.0,4/39,9.17%,STAT1;LY96;SOCS1;TNFRSF1A
168,prerank,KEGG_2021_Human__Natural killer cell mediated cytotoxicity,0.4733728961621887,0.8441941630210666,0.6851642129105323,1.0,1.0,9/46,9.58%,TNFSF10;SH2D1B;FAS;BID;LCP2;FCER1G;ICAM1;FCGR3B;HCST
169,prerank,MSigDB_Hallmark_2020__IL-2/STAT5 Signaling,0.4622611041338667,0.8378907267905286,0.7173219978746015,1.0,1.0,13/74,10.06%,TNFSF10;IFITM3;CAPG;ANXA4;SELL;CXCL10;SMPDL3A;SOCS1;GPR65;CST7;LTB;DENND5A;CTSZ
170,prerank,KEGG_2021_Human__Complement and coagulation cascades,0.49534619423673737,0.8357148325498999,0.6671469740634006,1.0,1.0,3/15,10.50%,C4A;CFB;CR1L
171,prerank,KEGG_2021_Human__Lysosome,0.4668755010224114,0.831480869327121,0.7150715071507151,1.0,1.0,9/56,11.94%,CD63;CTSS;TCIRG1;GLA;LAPTM4A;CTSH;CTSZ;NAPSA;LAMP2
172,prerank,MSigDB_Hallmark_2020__TNF-alpha Signaling via NF-kB,0.4560933162692081,0.8254703816034243,0.7842535787321063,1.0,1.0,14/109,6.78%,DDX58;IFIT2;TAP1;NAMPT;IL15RA;CCL5;IRF1;BCL2A1;NFKB2;CXCL10;SLC2A6;RELB;PLEK;ICAM1
173,prerank,KEGG_2021_Human__Human T-cell leukemia virus 1 infection,0.4508585877476385,0.8243627529649626,0.7281449893390192,1.0,1.0,5/70,6.78%,B2M;IL15RA;NFKB2;RELB;ICAM1
174,prerank,KEGG_2021_Human__p53 signaling pathway,0.4737150656630005,0.823189466347785,0.6703146374829001,1.0,1.0,3/22,5.49%,SHISA5;FAS;BID
175,prerank,KEGG_2021_Human__Tuberculosis,0.4528180936941373,0.8202846998943129,0.7422037422037422,1.0,1.0,16/80,14.02%,STAT1;CTSS;CLEC4E;TCIRG1;BID;FCER1G;SRC;FCGR3B;TNFRSF1A;LSP1;CR1L;RIPK2;LAMP2;FCGR1A;IL10RA;CD74
176,prerank,KEGG_2021_Human__Epithelial cell signaling in Helicobacter pylori infection,0.4616321669555872,0.8174628069664116,0.7158403869407497,1.0,1.0,6/36,11.71%,CCL5;NOD1;TCIRG1;SRC;CXCR2;ATP6V1F
177,prerank,KEGG_2021_Human__Autophagy,-0.26418640656789183,-0.8171740942358247,0.8105263157894737,0.7930499435075364,1.0,11/62,13.25%,PTEN;AKT1;RB1CC1;ULK2;KRAS;PIK3CB;PIK3CD;STK11;MAPK1;DAPK1;DDIT4
178,prerank,KEGG_2021_Human__Vasopressin-regulated water reabsorption,-0.3266206686757569,-0.8100296874543527,0.7231404958677686,0.797767200896298,1.0,1/21,1.10%,CREB5
179,prerank,MSigDB_Hallmark_2020__Adipogenesis,-0.25486474893335487,-0.8078858903687861,0.881578947368421,0.7937818073295742,1.0,8/67,9.78%,GPD2;TOB1;CCNG2;ALDH2;ARL4A;TKT;BCL6;ACOX1
180,prerank,MSigDB_Hallmark_2020__Apoptosis,0.44137938314050995,0.8052353201526801,0.7518959913326111,1.0,1.0,11/71,9.06%,TAP1;TNFSF10;IFITM3;IRF1;FAS;BID;RNASEL;GPX1;LGALS3;CASP7;CD38
181,prerank,KEGG_2021_Human__Huntington disease,0.4401103632942871,0.8011805493595222,0.8250758341759353,1.0,1.0,42/136,19.56%,PSMA3;NDUFA7;NDUFA13;PSMA2;COX2;GPX1;NDUFA12;NDUFB7;NDUFB9;ATP5MC1;PSMB4;ATP5F1E;ATP5MC3;NDUFA4;ATP5PO;SOD1;PSMA1;NDUFB11;PSMB3;PSMB2;ATP5PD;COX1;PSMA6;AP2S1;ND1;ND5;PSMD14;NDUFV3;DCTN5;NDUFB3;ND4L;CASP3;ND4;NDUFA2;SOD2;PSMC5;ATP5MC2;CYTB;PSMC2;NDUFA6;DCTN2;ATP5F1C
182,prerank,KEGG_2021_Human__Transcriptional misregulation in cancer,0.44273719210779494,0.8011152432365268,0.746448087431694,1.0,1.0,4/58,5.39%,BAK1;LMO2;BCL2A1;ITGB7
183,prerank,KEGG_2021_Human__Protein processing in endoplasmic reticulum,0.4400637000931027,0.796049869508324,0.7741935483870968,1.0,1.0,2/74,1.69%,EIF2AK2;BAK1
184,prerank,KEGG_2021_Human__RNA transport,-0.2406378389118599,-0.7832305903322342,0.8857142857142857,0.8240304294080188,1.0,14/63,17.97%,EIF5;EIF4G2;EIF4A1;EIF1;EIF4G3;EEF1A1;EIF3I;PABPC1;ACIN1;SENP2;ALYREF;FXR2;EIF4B;TPR
185,prerank,KEGG_2021_Human__Hematopoietic cell lineage,-0.31743993898907363,-0.7764262017023834,0.75,0.8264965389961426,1.0,3/19,5.67%,TNF;ITGA4;ITGAM
186,prerank,KEGG_2021_Human__Prion disease,0.41728688414292,0.7614072118689215,0.8446700507614213,1.0,1.0,40/128,19.56%,PSMA3;CCL5;NDUFA7;NDUFA13;PSMA2;NCF2;COX2;NDUFA12;NDUFB7;NDUFB9;ATP5MC1;PSMB4;ATP5F1E;ATP5MC3;NDUFA4;ATP5PO;SOD1;PSMA1;NDUFB11;PSMB3;PSMB2;ATP5PD;COX1;PSMA6;ND1;ND5;PSMD14;NDUFV3;NDUFB3;ND4L;CASP3;ND4;ATF4;NDUFA2;PSMC5;ATP5MC2;CYTB;PSMC2;NDUFA6;ATP5F1C
187,prerank,KEGG_2021_Human__Thermogenesis,0.4180744252567239,0.7606854338260374,0.8064853556485355,1.0,1.0,29/87,20.41%,NDUFA7;NDUFA13;COX2;NDUFA12;ATP5MF;NDUFB7;NDUFB9;ATP5MC1;ATP5ME;ATP5F1E;ATP5MC3;NDUFA4;ATP5PO;NDUFB11;ATP5PD;COX1;ND1;ND5;NDUFV3;NDUFB3;ND4L;RHEB;ND4;NDUFA2;ATP5MC2;CYTB;NDUFA6;ATP5F1C;NDUFS6
188,prerank,KEGG_2021_Human__SNARE interactions in vesicular transport,0.4365246789250229,0.7523304847829858,0.7334254143646409,1.0,1.0,3/20,16.82%,VAMP8;GOSR2;STX5
189,prerank,MSigDB_Hallmark_2020__UV Response Up,0.4147039261051386,0.7476226374256535,0.7815217391304348,1.0,1.0,6/59,6.91%,BAK1;TAP1;IRF1;BID;ICAM1;ALAS1
190,prerank,KEGG_2021_Human__Hippo signaling pathway,-0.25858359719621016,-0.7455692638527237,0.8625,0.8575882061591352,1.0,9/39,20.44%,TPTEP2-CSNK1E;GSK3B;PPP1CB;RASSF2;SMAD7;PAK1;CTNNB1;ITGB2;ACTB
191,prerank,KEGG_2021_Human__Melanoma,0.4278931624101737,0.7375959273158598,0.772785622593068,1.0,1.0,1/24,1.69%,BAK1
192,prerank,KEGG_2021_Human__AGE-RAGE signaling pathway in diabetic complications,0.4051944030167847,0.7268021964563025,0.7838785046728972,1.0,1.0,1/40,1.18%,STAT1
193,prerank,KEGG_2021_Human__Diabetic cardiomyopathy,0.3990810177222646,0.7260497112038378,0.855072463768116,1.0,1.0,31/92,20.85%,NDUFA7;NDUFA13;NCF2;COX2;NDUFA12;MPC2;GAPDH;NDUFB7;NDUFB9;ATP5MC1;ATP5F1E;ATP5MC3;NDUFA4;ATP5PO;NDUFB11;ATP5PD;COX1;ND1;ND5;PDHB;NDUFV3;NDUFB3;ND4L;ND4;NDUFA2;ATP5MC2;CYTB;NDUFA6;ATP5F1C;NDUFS6;G6PD
194,prerank,MSigDB_Hallmark_2020__PI3K/AKT/mTOR  Signaling,0.4034045787517823,0.7224633883463719,0.7986725663716814,1.0,1.0,11/55,14.79%,STAT2;NOD1;DAPP1;ARPC3;TNFRSF1A;CFL1;TBK1;IL2RG;ARHGDIA;NFKBIB;SLA
195,prerank,KEGG_2021_Human__Salmonella infection,0.39803468135457704,0.7207940919834288,0.8904665314401623,1.0,1.0,14/121,9.65%,BAK1;TNFSF10;LY96;NOD1;MLKL;NLRC4;DYNLT1;DYNLRB1;ARPC3;GSDMD;GAPDH;CASP7;TNFRSF1A;BRK1
196,prerank,KEGG_2021_Human__Th1 and Th2 cell differentiation,0.4154245822094876,0.7172948426425209,0.7674714104193139,1.0,1.0,1/25,1.18%,STAT1
197,prerank,KEGG_2021_Human__Amyotrophic lateral sclerosis,0.39630062399125715,0.7166971106133572,0.9133937562940584,1.0,1.0,47/159,19.56%,PSMA3;NDUFA7;NDUFA13;PSMA2;COX2;BID;GPX1;NDUFA12;NDUFB7;NDUFB9;ATP5MC1;GABARAPL2;TNFRSF1A;RAB8A;PSMB4;ATP5F1E;ATP5MC3;NDUFA4;ATP5PO;SOD1;PSMA1;NDUFB11;TBK1;PSMB3;PSMB2;ATP5PD;COX1;PSMA6;ND1;ND5;PSMD14;NDUFV3;DCTN5;TANK;NDUFB3;ND4L;CASP3;ND4;ATF4;NDUFA2;PSMC5;ATP5MC2;CYTB;PSMC2;NDUFA6;DCTN2;ATP5F1C
198,prerank,KEGG_2021_Human__Thyroid hormone signaling pathway,0.40016473278066483,0.714824606191175,0.7961711711711712,1.0,1.0,1/45,1.18%,STAT1
199,prerank,KEGG_2021_Human__Th17 cell differentiation,0.39780293324830424,0.7084322825238468,0.799761620977354,1.0,1.0,1/36,1.18%,STAT1
200,prerank,KEGG_2021_Human__Endometrial cancer,0.40813287200039505,0.7081198521144297,0.7864321608040201,1.0,1.0,1/28,1.69%,BAK1
201,prerank,KEGG_2021_Human__Alzheimer disease,0.38724790469264386,0.7057276983052364,0.9346076458752515,1.0,1.0,45/161,19.56%,EIF2AK2;PSMA3;NDUFA7;FAS;NDUFA13;PSMA2;COX2;BID;NDUFA12;GAPDH;NDUFB7;NDUFB9;CASP7;ATP5MC1;TNFRSF1A;PSMB4;ATP5F1E;ATP5MC3;NDUFA4;ATP5PO;PSMA1;NDUFB11;PSMB3;PSMB2;ATP5PD;COX1;PSMA6;PSENEN;ND1;ND5;PSMD14;NDUFV3;NDUFB3;ND4L;CASP3;ND4;ATF4;NDUFA2;ADAM17;PSMC5;ATP5MC2;CYTB;PSMC2;NDUFA6;ATP5F1C
202,prerank,KEGG_2021_Human__Non-small cell lung cancer,0.39163304826652073,0.688867934487045,0.8355663824604141,1.0,1.0,1/35,1.69%,BAK1
203,prerank,MSigDB_Hallmark_2020__Myc Targets V1,0.3698542788507551,0.6717314439315688,0.8825995807127882,1.0,1.0,28/88,23.26%,PSMA2;UBE2L3;YWHAQ;DEK;SNRPD2;EIF2S2;PSMA1;RPL14;PSMB3;PSMB2;CCT4;PSMA6;PSMD14;EIF3D;CCT7;RPL22;EIF4H;RPS5;YWHAE;CLNS1A;TXNL4A;LSM7;PSMA4;CCT5;RPS6;HNRNPA2B1;RPL34;RPL6
204,prerank,KEGG_2021_Human__Chemokine signaling pathway,0.37040842229218984,0.6713404074928351,0.8794549266247379,1.0,1.0,5/80,6.32%,STAT1;STAT2;CCL5;CXCL10;SRC
205,prerank,KEGG_2021_Human__Small cell lung cancer,0.38213908376089467,0.6569231250971295,0.8372395833333334,1.0,1.0,1/24,1.69%,BAK1
206,prerank,MSigDB_Hallmark_2020__Protein Secretion,0.3627541536421852,0.6537726206060118,0.88998899889989,1.0,1.0,9/56,15.69%,CD63;COPE;GOSR2;GLA;ATP1A1;LAMP2;SOD1;AP2S1;ABCA1
207,prerank,KEGG_2021_Human__PD-L1 expression and PD-1 checkpoint pathway in cancer,0.3697634467313459,0.653176083723466,0.8564867967853043,1.0,1.0,2/44,3.21%,STAT1;CD274
208,prerank,KEGG_2021_Human__Pathogenic Escherichia coli infection,0.3587843205718567,0.6509552342703011,0.890295358649789,1.0,1.0,11/77,10.58%,BAK1;TNFSF10;FAS;MYH11;SRC;ARPC3;GAPDH;CASP7;TNFRSF1A;BRK1;HCLS1
209,prerank,MSigDB_Hallmark_2020__E2F Targets,0.3689345294250975,0.6500727671764814,0.8355029585798817,1.0,1.0,12/37,23.21%,JPT1;LMNB1;DEK;PNN;TACC3;NAA38;RFC1;PHF5A;SNRPB;EED;SMC6;HMGB2
210,prerank,KEGG_2021_Human__Mitophagy,0.3652071044334428,0.6498370498135625,0.8721351025331725,1.0,1.0,11/37,23.06%,CALCOCO2;SRC;USP15;GABARAPL2;TBK1;UBB;ATF4;RRAS;HIF1A;USP8;TFE3
211,prerank,MSigDB_Hallmark_2020__mTORC1 Signaling,0.3521583555868334,0.6493867352627586,0.8982346832814122,1.0,1.0,17/96,14.79%,PSMA3;NAMPT;WARS1;GLRX;DAPP1;GAPDH;GLA;NMT1;ATP5MC1;SEC11A;EIF2S2;IFI30;TBK1;NFKBIB;PFKL;PSMD14;SLA
212,prerank,KEGG_2021_Human__Glycolysis / Gluconeogenesis,0.3865290191820393,0.6466321302236414,0.84,1.0,1.0,6/20,17.30%,AKR1A1;GAPDH;PFKL;PDHB;PKM;HK3
213,prerank,KEGG_2021_Human__Non-alcoholic fatty liver disease,0.3559900538242665,0.642156475928793,0.8939554612937434,1.0,1.0,23/78,21.26%,NDUFA7;FAS;NDUFA13;COX2;BID;NDUFA12;NDUFB7;NDUFB9;CASP7;TNFRSF1A;NDUFA4;NDUFB11;COX1;NDUFV3;NDUFB3;CASP3;ATF4;NDUFA2;CYTB;NDUFA6;NDUFS6;XBP1;ITCH
214,prerank,KEGG_2021_Human__Chronic myeloid leukemia,0.3605927758053837,0.6416309643769499,0.8586448598130841,1.0,1.0,1/38,1.69%,BAK1
215,prerank,KEGG_2021_Human__Leishmaniasis,0.35669708200302963,0.633691091950681,0.8672985781990521,1.0,1.0,3/37,7.52%,STAT1;NCF2;FCGR3B
216,prerank,MSigDB_Hallmark_2020__Cholesterol Homeostasis,0.3593515314635779,0.6240401960795027,0.8553299492385786,1.0,1.0,6/23,16.82%,MVD;LGALS3;ETHE1;ANTXR2;ANXA5;STX5
217,prerank,KEGG_2021_Human__TNF signaling pathway,0.34772841639997937,0.6161304310879631,0.9021134593993326,1.0,1.0,8/49,9.17%,CCL5;IRF1;FAS;MLKL;CXCL10;ICAM1;CASP7;TNFRSF1A
218,prerank,KEGG_2021_Human__Pathways in cancer,0.323976125476984,0.5893143983763118,0.96579476861167,1.0,1.0,8/158,5.60%,STAT1;BAK1;STAT2;IL15RA;FAS;ELOB;BID;NFKB2
219,prerank,KEGG_2021_Human__Colorectal cancer,0.3257942833836389,0.5814128250372096,0.9100346020761245,1.0,1.0,1/42,1.69%,BAK1
220,prerank,KEGG_2021_Human__Neutrophil extracellular trap formation,0.32306801485445635,0.579264022341708,0.9215017064846417,1.0,1.0,7/47,12.63%,FPR2;NCF2;SRC;FCGR3B;GSDMD;CR1L;FCGR1A
221,prerank,KEGG_2021_Human__Retrograde endocannabinoid signaling,0.3189859004670679,0.5763499791853303,0.9192825112107623,1.0,1.0,17/51,20.41%,NDUFA7;NDUFA13;NDUFA12;NDUFB7;NDUFB9;NDUFA4;NDUFB11;ND1;ND5;NDUFV3;NDUFB3;ND4L;GNG5;ND4;NDUFA2;NDUFA6;NDUFS6
222,prerank,KEGG_2021_Human__Spliceosome,0.31591281840083313,0.5656914967108064,0.9560557341907824,1.0,1.0,33/78,29.22%,SYF2;SNRPE;U2AF1L4;SNRPD2;LSM4;RBM17;SNRPC;PUF60;SF3B5;PPIH;PRPF38A;SF3A3;BUD31;RBM22;PHF5A;SNRPB;MAGOH;TXNL4A;LSM7;SMNDC1;PRPF18;HNRNPM;SNW1;CWC15;CDC40;SNRNP27;LSM3;PQBP1;RP9;SART1;SNRNP40;SF3B6;U2AF1
223,prerank,MSigDB_Hallmark_2020__Apical Junction,0.3159444286074585,0.5507690627039944,0.9419279907084785,1.0,1.0,4/45,6.78%,CD274;MVD;SRC;ICAM1
224,prerank,KEGG_2021_Human__Peroxisome,0.3189765353488552,0.548934089416373,0.8918918918918919,1.0,1.0,4/18,18.97%,XDH;SOD1;SOD2;HMGCL
225,prerank,MSigDB_Hallmark_2020__Coagulation,0.31249451856581895,0.5420958991677078,0.9327731092436975,1.0,1.0,7/34,20.54%,CFB;PLEK;CTSH;LAMP2;F2RL2;OLR1;S100A13
226,prerank,MSigDB_Hallmark_2020__Reactive Oxygen Species Pathway,0.2891703594598999,0.5108335246284685,0.9353233830845771,1.0,1.0,8/30,20.85%,GLRX;MGST1;LSP1;SOD1;SOD2;LAMTOR5;NDUFA6;G6PD
227,prerank,KEGG_2021_Human__Shigellosis,0.27507832871874777,0.5030723630404407,0.9816700610997964,1.0,1.0,17/111,14.30%,CCL5;NOD1;CALCOCO2;NLRC4;STING1;SRC;RNF31;ARPC3;GABARAPL2;TNFRSF1A;U2AF1L4;HCLS1;RIPK2;TBK1;UBB;ATG12;NFKBIB
228,prerank,KEGG_2021_Human__Spinocerebellar ataxia,0.2779814824983863,0.502894767826254,0.976318622174381,1.0,1.0,8/61,14.74%,PSMA3;PSMA2;PSMB4;PSMA1;PSMB3;PSMB2;PSMA6;PSMD14
229,prerank,KEGG_2021_Human__Legionellosis,0.28231471897427507,0.49115299389091815,0.9672131147540983,1.0,1.0,7/29,18.56%,NLRC4;NFKB2;CASP7;CR1L;CASP3;SAR1A;EEF1G
230,prerank,MSigDB_Hallmark_2020__Bile Acid Metabolism,0.2518330100153757,0.43272448539252406,0.9661266568483063,1.0,1.0,5/15,25.03%,SOD1;HSD17B11;ABCA1;ABCD1;ALDH9A1
231,prerank,KEGG_2021_Human__Endocytosis,0.22814931412616765,0.4104066123011653,1.0,1.0,1.0,20/115,17.95%,VPS28;SRC;CHMP5;ARPC3;ARF5;EHD1;VPS29;CXCR2;RAB8A;WASHC3;IL2RG;SNF8;VPS26A;AP2S1;SH3GLB1;VTA1;VPS25;MVB12A;WASHC2C;CHMP2A
232,prerank,MSigDB_Hallmark_2020__Pperoxisome,0.22482533115923434,0.3964781934755031,0.9924717691342535,1.0,1.0,10/28,30.37%,SOD1;HSD17B11;SOD2;HMGCL;ITGB1BP1;ABCD1;ALDH9A1;DHRS3;PRDX1;SCP2
233,prerank,KEGG_2021_Human__mRNA surveillance pathway,0.16782908299054478,0.3006531784657037,1.0,0.9998096926536356,1.0,5/40,18.33%,SSU72;PNN;PPP2R1A;PPP2R3C;MAGOH
